Tips for Pharmaceutical Manufacturing Scale-Up & Tech Transfer

In our scenario, a mid-sized pharmaceutical company conducted its first commercial batch of a monoclonal antibody, which revealed significant variances in product characteristics compared to previously approved batches. Signals on…

Timely identification of symptoms indicative of regulatory concerns is critical in maintaining compliance. Some key signals include:Click to read the full article.

Identifying failure signals is crucial in managing the regulatory filing impact of scale-up processes. Here are some key symptoms:Click to read the full article.

Identifying symptoms that indicate the potential for regulatory filing issues during scale-up is paramount. Common signals include:Click to read the full article.

Identifying early warning signs of potential compliance issues during the scale-up process is critical. Symptoms can manifest in various forms, including:Click to read the full article.

Identifying symptoms indicating that changes in PAT may necessitate a regulatory filing is essential for timely action. Common signals include:Click to read the full article.

Recognizing symptoms signaling the need for an evaluation of your PAT implementation is the first step in maintaining compliance and operational efficiency. Look for the following indications:Click to read the…

During the scale-up process, various symptoms may signal impending regulatory issues. Identifying these early can save significant time and resources. Common signals include:Click to read the full article.

Shortly after batch production commenced, Quality Control (QC) team members noted abnormal product characteristics linked to a specific lot of a biologic product. These symptoms included:Click to read the full…

In our case study, employees in the production area began reporting issues with the stability of an injectable product during a routine stability assessment. Key symptoms detected included:Click to read…

When facing regulatory queries, the first signs often manifest as unexpected deviations in scale-up data or inconsistencies in process performance metrics. Typical symptoms may include:Click to read the full article.

One of the first signs of potential regulatory concerns is the emergence of unexpected variability in scale-up data. Symptoms may include:Click to read the full article.